# DARE — Dare Bioscience Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** DARE  
**Sources:** 20  
**Published:** 2026-10-13  
**Canonical:** https://app.k3vl4r.com/research/deep-research-dare-dare-bioscience-inc-catalysts-narrative-risks-7227

---

## Snapshot (as of 2026‑10‑12)

Daré Bioscience (NASDAQ: DARE) is a San Diego–headquartered, micro‑cap women's health company founded in 2015 that describes itself as transitioning from a clinical‑stage developer to a multi‑product commercial women's health business [[4]](https://markets.businessinsider.com/news/stocks/dar-bioscience-ceo-sabrina-martucci-johnson-named-to-forbes-2026-50-over-50-innovation-list-1036470387), [[19]](https://stockanalysis.com/stocks/dare/), [[20]](https://finance.yahoo.com/quote/DARE/). As of Oct 12, 2026, the stock closed near $0.75 (down ~3% that day) with a market capitalization of roughly $14.75M on ~19.67M shares outstanding [[14]](https://stockanalysis.com/stocks/dare/forecast/), [[19]](https://stockanalysis.com/stocks/dare/). An earlier snapshot placed market cap near $15.2M as of Oct 10, 2026 [background]. Critically, the share price has fallen approximately 64.6% over the trailing year [[14]](https://stockanalysis.com/stocks/dare/forecast/) — a steep decline that deserves attention given the steady flow of positive corporate announcements. (Price data is provided for context, not as a recommendation.)

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-dare-dare-bioscience-inc-catalysts-narrative-risks-7227 (free to sign up)._